Shares of Threshold Pharmaceuticals (NASDAQ: THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (CELG) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.
S&P 500
5,989.21
+0.3%
+$18.40
DJI
42,550.03
+0.3%
+$122.29
NASDAQ
19,550.88
+0.5%
+$90.39
Bitcoin
104,378.00
-0.9%
-906.37
AAPL
$203.10
+0.1%
+$0.28
AMZN
$210.86
+1.8%
+$3.63
GOOG
$171.59
+1.3%
+$2.20
META
$689.70
+0.3%
+$1.75
MSFT
$468.10
+0.9%
+$4.24
NVDA
$143.00
+0.8%
+$1.08
TSLA
$313.19
-5.7%
-$18.86
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Threshold's Window of Success Reopens
By Dave Williamson
–
Jan 23, 2013 at 9:14PM
NASDAQ: CELG
Celgene
Why Threshold popped today.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Celgene
CELG
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Here's Why Editas Medicine Jumped 45.3% in November
Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better
Better Buy: Biogen vs. Celgene
Better Buy: Geron vs. Celgene
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.